secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001213900-24-023188
Event type: litigation
Sentiment:  positive
Materiality: 0.60
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax regains Nasdaq compliance; court approves settlement with Sorrento/Scilex
--------------------------------------------------------------------------------

- Nasdaq notified Virpax that closing bid price was at $1.00 or greater for 10 consecutive business days through March 14, 2024; compliance regained.
- Bankruptcy Court for Southern District of Texas entered order approving settlement between Virpax, Sorrento Therapeutics, and Scilex Pharmaceuticals on March 14, 2024.
- Settlement Agreement and Mutual Release incorporated by reference from prior 8-K; no financial terms disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024023188/0001213900-24-023188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024023188/ea0201947-8k_virpaxphrm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-023188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer